FrancophonIA/ELRC3.0 huggingface dataset:
English: However, if your child gets any of these symptoms you should contact a doctor urgently.
Croatian: Međutim, ako Vaše dijete dobije sljedeće simptome hitno kontaktirajte liječnika.
English: Data in pregnant women collected as part of pregnancy registries, epidemiological studies and inadvertent exposure during clinical trials are insufficient to conclude whether or not vaccination with Cervarix affects the risk of adverse pregnancy outcomes including spontaneous abortion.
Croatian: Podaci o trudnicama, prikupljeni iz registara trudnoće, epidemioloških ispitivanja i nenamjerne izloženosti tijekom kliničkih ispitivanja, nedostatni su da bi se moglo zaključiti utječe li cijepljenje cjepivom Cervarix ili ne na rizik od neželjenih ishoda trudnoće uključujući spontani pobačaj.
English: HPV 45, -31 and -33 are the 3 most common non-vaccine HPV types identified in squamous cervical carcinoma (12.1%) and adenocarcinoma (8.5%).
Croatian: HPV 45, -31 i -33 su 3 najčešća HPV tipa za koje ne postoji cjepivo, a koji su identificirani u karcinomu pločastog epitela cerviksa (12,1%) i adenokarcinomu (8,5%).
English: If not used immediately, the vaccine should be stored in a refrigerator (2°C - 8°C).
Croatian: Ako se ne upotrijebi odmah, cjepivo se mora čuvati u hladnjaku (2°C - 8°C).
English: Cervarix is not infectious and so, it cannot cause HPV related diseases.
Croatian: Cervarix nije zarazan te stoga ne može uzrokovati bolest povezanu s HPV-om.
English: GlaxoSmithKline Biologicals S.A. 89, rue de l'Institut BE-1330 Rixensart Belgium
Croatian: GlaxoSmithKline Biologicals S.A. 89, rue de l'Institut BE-1330 Rixensart Belgija
English: Pharmacotherapeutic group: Vaccines, Papillomavirus vaccines, ATC code: J07BM02
Croatian: Farmakoterapijska skupina: cjepiva, cjepiva protiv papilomavirusa, ATK oznaka: J07BM02 Mehanizam djelovanja
English: Includes 15% of subjects with previous history of HPV disease/infection
Croatian: Uključuje 15% ispitanica s prethodnom HPV infekcijom/bolešću u anamnezi.
English: If not used at the end of this period the vaccine should be discarded.
Croatian: Ako se ne upotrijebi do kraja tog razdoblja, cjepivo treba zbrinuti u otpad.
English: However, individuals already infected (HPV DNA positive) with one of the vaccine-related HPV types prior to vaccination were protected from clinical disease caused by the other vaccine HPV type.
Croatian: Međutim, osobe koje su prije cijepljenja već bile inficirane (HPV DNA pozitivne) s jednim od HPV tipova protiv kojih je cjepivo namijenjeno, bile su zaštićene od kliničkih bolesti uzrokovanih ostalim HPV tipovima protiv kojih je cjepivo namijenjeno.
English: HPV-31, 33 and 45 showed consistent cross-protection for 6-month persistent infection and CIN2+ endpoints in all study cohorts.
Croatian: HPV-31, 33 i 45 pokazali su dosljednu križnu zaštitu za 6-mjesečne perzistentne infekcije i CIN2+ ishode u svim kohortama ispitivanja.
English: Please speak to your doctor for more information.
Croatian: Za više informacija o tome upitajte svog liječnika.
English: Overall, the proportions of pregnant subjects who experienced specific outcomes (e.g., normal infant, abnormal infants including congenital anomalies, premature birth, and spontaneous abortion) were similar between treatment groups.
Croatian: Općenito se može reći da su udjeli trudnica sa specifičnim ishodima trudnoće (npr. normalno dojenče, dojenče s oštećenjima uključujući kongenitalne anomalije, preuranjeni porod i spontani pobačaj) bili slični između liječenih skupina.
English: Other HPV types can also cause ano-genital cancers.
Croatian: Ostali HPV tipovi mogu također uzrokovati različite oblike raka anusa i spolnih organa.
English: The vaccine is therefore not indicated for treatment of cervical cancer or cervical intraepithelial neoplasia (CIN).
Croatian: Cjepivo stoga nije indicirano za liječenje karcinoma cerviksa ili cervikalne intraepitelne neoplazije (CIN).
English: As Cervarix will not protect against all types of Human Papillomavirus, appropriate precautions against exposure to HPV and sexually transmitted diseases should continue to be used.
Croatian: Budući da Cervarix ne štiti od svih tipova humanog papilomavirusa, i dalje treba primjenjivati odgovarajuće preventivne mjere za sprječavanje zaraze HPV-om i ostalim spolno prenosivim bolestima.
English: The data showed comparable immunogenicity in males and females.
Croatian: Podaci su pokazali usporedivu imunogenost kod ispitanika muškog i ženskog spola.
English: Administration of Cervarix should be postponed in subjects suffering from an acute severe febrile illness.
Croatian: Primjenu cjepiva Cervarix potrebno je odgoditi u osoba koje imaju tešku akutnu febrilnu bolest.
English: First injection: at chosen date
Croatian: Prva injekcija: odabranoga dana
English: There was no evidence of protection from disease caused by the HPV types for which subjects were HPV DNA positive at study entry.
Croatian: Nema dokaza za zaštitu od bolesti uzrokovane HPV tipovima na koje su ispitanice bile HPV DNA pozitivne kod ulaska u ispitivanje.
English: Cervarix is for intramuscular injection in the deltoid region (see also sections 4.4 and 4.5).
Croatian: Način primjene Cervarix se primjenjuje intramuskularnom injekcijom u deltoidno područje (vidjeti također dijelove 4.4 i 4.5).
English: Contents of the pack and other information What Cervarix contains - The active substances are: Human Papillomavirus1 type 16 L1 protein2,3,4
Croatian: Sadržaj pakiranja i druge informacije Što Cervarix sadrži - Djelatne tvari su: humani papilomavirus1 tip 16 L1 protein2,3,4
English: The study was not powered to demonstrate a difference between the vaccine and the control group for these endpoints.
Croatian: Studija nije imala snagu pokazati razliku između grupe cijepljenih i kontrolne grupe za ove ishode.
English: In study 023 (a subset of study 001/007), the immune response continued to be evaluated up to 113 months.
Croatian: U ispitivanju 023 (podskup ispitivanja 001/007), imunološki odgovor je promatran sljedećih 113 mjeseci.
English: • other injection site reactions such as hard lump, tingling or numbness.
Croatian: • ostale reakcije na mjestu primjene poput tvrde kvržice, trnaca ili utrnulosti.
English: As with other vaccines, an adequate immune response may not be elicited in these individuals.
Croatian: Kao i kod drugih cjepiva, u tih osoba možda se neće postići odgovarajući imunološki odgovor.
English: 3-O-desacyl-4'- monophosphoryl lipid A (MPL)3
Croatian: 3-O-desacil-4'-monofosforil lipid A (MPL)3
English: The secondary endpoints included 6- and 12-month persistent infection.
Croatian: Sekundarni ishodi uključivali su 6- i 12-mjesečne perzistentne infekcije.
English: There is no evidence whether prevention of persistent infection that lasts for at least 6 months is a relevant surrogate marker for cervical cancer prevention in women aged 26 years and above.
Croatian: Nema dokaza o tome je li prevencija perzistentne infekcije koja traje najmanje 6 mjeseci relevantan surogat markera za prevenciju karcinoma cerviksa u žena u dobi od 26 i više godina.
English: Cervarix will only protect against diseases that are caused by HPV types 16 and 18 and to some extent against diseases caused by certain other oncogenic related HPV types (see section 5.1).
Croatian: Cervarix samo štiti od bolesti uzrokovanih HPV tipovima 16 i 18 i do određene mjere protiv bolesti uzrokovanih drugim onkogenim HPV tipovima (vidjeti dio 5.1).
English: 0.5 milligrams Al3+ in total
Croatian: ukupno 0,5 mg Al3+
English: 6-month persistent infection
Croatian: 6-mjesečna perzistentna infekcija
English: There are no safety, immunogenicity or efficacy data to support interchangeability of Cervarix with other HPV vaccines.
Croatian: Nema podataka o sigurnosti primjene, imunogenosti niti djelotvornosti koji bi podržali zamjenjivost cjepiva Cervarix s drugim HPV cjepivima.
English: At the end of study analysis, Cervarix reduced definitive cervical therapy procedures (includes loop electrosurgical excision procedure [LEEP], cold-knife Cone, and laser procedures) by 70.2% (95% CI: 57.8;79.3) in TVC-naïve and 33.2% (95% CI: 20.8;43.7) in TVC.
Croatian: U analizi na kraju ispitivanja, Cervarix je smanjio konačne procedure cervikalne terapije (uključuje postupak elektrokirurške ekscizije [LEEP], konizaciju hladnim nožem kao i laserske procedure) za 70,2% (95%CI: 57,8;79,3) u TVC „naïve“ i za 33,2% (95%CI: 20,8;43,7) u TVC.
English: To attach the needle to the syringe, twist the needle clockwise into the syringe until you feel it lock.
Croatian: Pričvrstite iglu na štrcaljku okrećući iglu u smjeru kretanja kazaljki na satu dok ne osjetite da je učvršćena.
English: The primary analyses of efficacy were performed on the ATP cohort for efficacy and the TVC which included a subset of up to 15% of women with a history of HPV-associated infection or disease (defined as two or more abnormal smears in sequence, abnormal colposcopy, or biopsy or treatment of the cervix after abnormal smear or colposcopy findings).
Croatian: Primarne analize djelotvornosti provedene su u ATP kohorti za djelotvornost i u TVC koja je uključivala podskupinu do 15% žena s infekcijom ili bolešću povezanom s HPV-om (što se definiralo kao dva ili više uzastopnih abnormalnih nalaza cervikalnog brisa, abnormalni nalaz kolposkopije, ili biopsija ili liječenje cerviksa nakon abnormalnih nalaza cervikalnog brisa ili kolposkopije) u anamnezi.
English: Cervarix will not protect against other diseases that are not caused by Human Papillomavirus.
Croatian: Cervarix ne pruža zaštitu od drugih bolesti koje nisu uzrokovane humanim papilomavirusom.
English: 58, 59, 66 and 68 - Were seronegative for HPV-16 and HPV-18 and - Had normal cytology
Croatian: 59, 66 i 68 - bile seronegativne na HPV-16 i HPV-18 i - imale normalan citološki nalaz.
English: Antibody titers peaked at month 7 then gradually declined up to month 18 and stabilized to reach a plateau up to month 84.
Croatian: Titri protutijela dosegli su vršnu vrijednost u 7. mjesecu, nakon čega su postupno padali sve do 18. mjeseca te se stabilizirali dosegnuvši plato do 84. mjeseca.
English: Vaccination is not a substitute for routine cervical screening.
Croatian: Cijepljenje nije zamjena rutinskom pregledu cerviksa.
English: 6.5 Nature and contents of container
Croatian: 6.5 Vrsta i sadržaj spremnika Napunjena štrcaljka
English: N = number of subjects included in each group n = number of cases (1) TVC: includes all vaccinated subjects (who received at least one dose of vaccine) irrespective of
Croatian: N = broj ispitanika uključenih u pojedinu skupinu n = broj slučajeva (1) TVC: uključuje sve cijepljene ispitanike (koji su primili bar jednu dozu cjepiva) neovisno o početnom
English: Similar results were observed when Cervarix was given concomitantly with Engerix B with 97.9% of subjects reaching anti-HBs ≥ 10mIU/ml compared to 100% for Engerix B given alone.
Croatian: Slični rezultati su primijećeni kod istodobne primjene cjepiva Cervarix i Engerix B, gdje je udio ispitanika koji su dosegli anti-HBs ≥ 10 mIU/ml 97,9% u usporedbi sa 100% za Engerix B primijenjen samostalno.
English: It is recommended that subjects who receive a first dose of Cervarix complete the vaccination course with Cervarix (see section 4.4).
Croatian: Preporučuje se da osobe koje prime prvu dozu cjepiva Cervarix dovrše ciklus cijepljenja cjepivom Cervarix (vidjeti dio 4.4).
English: In the TVC and TVC-naïve cohorts, the vaccine's efficacy was demonstrated against high-grade cervical lesions at end of study (Table 5).
Croatian: U TVC i TVC-neizloženim kohortama, djelotvornost cjepiva je pokazana na cervikalnim lezijama visokog stupnja na kraju ispitivanja (Tablica 5).
English: Efficacy against HPV types 16 and 18 in women with and without prior infection or disease.
Croatian: Djelotvornost protiv HPV tipova 16 i 18 u žena sa ili bez prethodne infekcije ili bolesti
English: Control (N = 8,708)
Croatian: Kontrola (N = 8708)
English: Use with systemic immunosuppressive medicinal products See section 4.4.
Croatian: Primjena sa sistemskim imunosupresivima Vidjeti dio 4.4.
English: Cervarix is not recommended for use below 9 years of age.
Croatian: Cervarix se ne preporučuje za uporabu u osoba mlađih od 9 godina.
English: The proportion of subjects reaching anti-HBs ≥ 10mIU/ml was 98.3% for concomitant vaccination and 100% for Twinrix given alone.
Croatian: Udio ispitanika koji su dosegli anti-HBs ≥ 10 mIU/ml je 98,3% kod istodobne primjene i 100% za Twinrix samostalno.
English: Serological data suggest a transfer of anti-HPV-16 and anti-HPV-18 antibodies via the milk during the lactation period in rats.
Croatian: Serološki podaci ukazuju na prijenos anti-HPV-16 i anti-HPV-18 protutijela putem mlijeka tijekom razdoblja dojenja u štakora.
English: Women who are pregnant or trying to become pregnant, are advised to postpone or interrupt vaccination until completion of pregnancy.
Croatian: Trudnicama ili ženama koje pokušavaju zatrudnjeti preporučuje se odgoditi ili prekinuti cijepljenje do završetka trudnoće.
English: A subset of women (N=776) vaccinated in study 001 was followed in study 007 up to 6.4 years (approximately 77 months) after the first dose (mean follow-up of 5.9 years).
Croatian: Podskupina žena (N=776) cijepljena u ispitivanju 001 praćena je u ispitivanju 007 do 6,4 godine (približno 77 mjeseci) nakon prve doze (prosječni period praćenja 5,9 godina).
English: Overall impact of the vaccine on cervical HPV disease burden
Croatian: Sveukupni utjecaj cjepiva na opterećenje cervikalnom bolesti uzrokovanom HPV-om
English: Store in the original package in order to protect from light
Croatian: Ne zamrzavati Čuvati u originalnom pakiranju radi zaštite od svjetlosti
English: Bridging the efficacy of Cervarix from young adult women to adolescents
Croatian: Posredno zaključivanje o djelotvornosti cjepiva Cervarix u adolescentica, temeljem podataka iz mlađih odraslih žena
English: The antibody response to HPV-16 and HPV-18 was measured using a type-specific direct ELISA (version 2, MedImmune methodology, modified by GSK) which was shown to correlate with the pseudovirion-based neutralisation assay (PBNA).
Croatian: Odgovor protutijela protiv HPV-16 i HPV-18 je mjeren primjenom izravnih ELISA testova specifičnih za pojedini tip (verzija 2, MedImmune metodologija, izmijenjena od strane GSK), koji koreliraju s testovima neutralizacije pseudoviriona (PBNA).
English: Holding the syringe barrel in one hand (avoid holding the syringe plunger), unscrew the syringe cap by twisting it anticlockwise.
Croatian: Držeći valjak štrcaljke u jednoj ruci (izbjegavajte držanje za klip štrcaljke) odvrnite kapicu štrcaljke okrećući je suprotno kretanju kazaljke na satu.
English: There was no evidence of protection from disease caused by HPV in subjects aged 25 years and above who were DNA positive and/ or with abnormal cytology at study entry.
Croatian: Nije bilo dokaza zaštite od bolesti uzrokovane HPV-om u ispitanica u dobi od 25 i više godina koje su bile DNA pozitivne i/ili imale abnormalan citološki nalaz pri uključivanju u ispitivanje.
English: This post-hoc analysis excluded cases (in the vaccine group and in the control group) which were not considered to be causally associated with HPV-16 or HPV-18 infections acquired during the trial.
Croatian: Ova post-hoc analiza je isključivala slučajeve (u cijepljenoj i kontrolnoj grupi) za koje se nije smatralo da su uzročno povezani sa HPV-16 ili HPV-18 infekcijama zadobivenim tijekom ispitivanja.
English: Cervarix is a vaccine intended to protect from the age of 9 years against the diseases caused by infection with Human Papillomaviruses (HPV).
Croatian: Cervarix je cjepivo namijenjeno zaštiti osoba u dobi od 9 godina nadalje od bolesti koje uzrokuju infekcije humanim papilomavirusima (HPV).
English: The term “premalignant ano-genital lesions” in section 4.1 corresponds to high-grade Cervical Intraepithelial Neoplasia (CIN2/3), high-grade vulvar intraepithelial neoplasia (VIN2/3), high-grade vaginal intraepithelial neoplasia (VaIN2/3) and high-grade anal intraepithelial neoplasia (AIN 2/3).
Croatian: Naziv „premaligne anogenitalne lezije“ korišten u dijelu 4.1 odgovara nazivu cervikalna intraepitelna neoplazija visokog stupnja (CIN 2/3), vulvarna intraepitelna neoplazija visokog stupnja (VIN2/3), vaginalna intraepitelna neoplazija visokog stupnja (VaIN2/3) i analna intraepitelna neoplazija visokog stupnja (AIN 2/3).
English: However, studies conducted in girls aged 9 to 14 years (study HPV-071) and in women aged 18 to 45 years (study HPV-010) have consistently shown a higher immune response with Cervarix than with the comparator for which efficacy data against anal premalignant lesions are conclusive and have shown protection.
Croatian: Međutim, ispitivanja provedena u djevojčica u dobi od 9 do 14 godina (ispitivanje HPV-071) i žena u dobi od 18 do 45 godina (ispitivanje HPV-010) dosljedno su pokazivala jači imunološki odgovor uz Cervarix nego uz usporedno cjepivo za koje su podaci o djelotvornosti uvjerljivi te su pokazali zaštitu protiv premalignih analnih lezija.
English: If you do not finish the complete vaccination course (two or three injections depending on your age at vaccination), you may not get the best response and protection from the vaccination.
Croatian: Ako ne dovršite cijeli ciklus cijepljenja (dvije ili tri injekcije ovisno o Vašoj dobi kod cijepljenja),
English: Of these subjects, 100% (95% CI: 96.1;100) remained seropositive for HPV-16 and HPV-18 in the ELISA assay.
Croatian: Od navedenih ispitanica, 100% (95% CI: 96,1:100) ih je ostalo seropozitivno na HPV-16 i HPV-18 u ELISA testu.
English: You should continue to follow your doctor's advice on cervical smear/Pap test (test to screen for changes in cells of the cervix caused by an HPV infection) and preventative and protective measures.
Croatian: I dalje trebate slijediti savjete svog liječnika (ginekologa) o uzimanju cervikalnih briseva/Papa testu (test kojim se otkrivaju promjene na stanicama vrata maternice uzrokovane zarazom HPV-om) te preventivnim i zaštitnim mjerama.
English: Administration of Cervarix at the same time as Twinrix has shown no clinically relevant interference in the antibody response to the HPV and hepatitis A antigens.
Croatian: Istodobna primjena cjepiva Cervarix s cjepivom Twinrix nije pokazala klinički relevantnu interferenciju u imunološkom odgovoru antitijela na HPV i hepatitis A antigene.
English: % Efficacy (95% CI)
Croatian: % Djelotvornosti (95% CI)
English: Vaccine efficacy at study conclusion is summarised in the following table.
Croatian: Djelotvornost cjepiva na kraju ispitivanja sažeto je prikazana u sljedećoj tablici.
English: The vaccine should under no circumstances be administered intravascularly or intradermally.
Croatian: Cjepivo se ni pod kojim okolnostima ne smije primijeniti intravaskularno ili intradermalno.
English: Persistent infection that lasts for at least 6 months has also been shown to be a relevant surrogate marker for cervical cancer in women aged 15 to 25 years.
Croatian: Perzistentna infekcija koja je trajala bar 6 mjeseci također se pokazala kao relevantan klinički surogat markera za karcinom cerviksa u žena u dobi od 15 do 25 godina.
English: Ten years after administration of the first dose, 100% of subjects in the 15-25 years group, 99.2% in the 26-45 years group and 96.3% in the 46-55 years group were still seropositive for HPV-16, and 99.2%, 93.7% and 83.8% for HPV-18, respectively.
Croatian: Deset godina nakon primjene prve doze, 100% ispitanica u skupini 15-25 godina, 99,2% u skupini 26-45 godina i 96,3% u skupini 46-55 godina i dalje je bilo seropozitivno na HPV-16, dok ih je 99,2%, 93,7% odnosno 83,8% bilo seropozitivno na HPV-18.
English: 3adsorbed on aluminium hydroxide, hydrated (Al(OH)3)
Croatian: 3 adsorbiran na aluminijev hidroksid, hidratizirani (Al(OH)3)
English: Use with other vaccines
Croatian: Primjena s drugim cjepivima
English: Study 001/007, which included women from 15 to 25 years of age at the time of vaccination, evaluated the immune response against HPV-16 and HPV-18 up to 76 months after administration of the first vaccine dose.
Croatian: U ispitivanju 001/007, u kojem su bile uključene žene stare 15 do 25 godina u vrijeme cijepljenja, procjenjivao se imunološki odgovor protiv HPV-16 i HPV-18 sve do 76 mjeseci nakon primjene prve doze cjepiva.
English: Clinical efficacy in women aged 26 years and older The efficacy of Cervarix was assessed in a double-blind, randomised Phase III clinical trial (HPV-015) that included a total of 5,778 women aged 26-72 years (median: 37.0 years).
Croatian: Klinička djelotvornost u žena u dobi od 26 godina i više Djelotvornost cjepiva Cervarix procijenjena je u dvostruko slijepom, randomiziranom kliničkom ispitivanju faze III (HPV-015), koje je uključilo ukupno 5778 žena u dobi od 26 do 72 godine (medijan: 37,0 godina).
English: HPV DNA status, cytology and serostatus at baseline.
Croatian: HPV DNA statusu, citologiji i serostatusu.
English: Pack sizes of 1 and 10 pre-filled syringes with or without needles.
Croatian: Pakiranja od 1 i 10 štrcaljki s ili bez igle.
English: However, stability has been demonstrated when stored outside the refrigerator for up to 3 days at temperatures between 8°C and 25°C or for up to 1 day at temperatures between 25°C and 37°C.
Croatian: dokazana je stabilnost pri čuvanju izvan hladnjakado 3 dana na temperaturi između 8°C i 25°C ili do 1 dan na temperaturi između 25°C i 37°C.
English: Cervarix is a vaccine for use from the age of 9 years for the prevention of premalignant ano-genital lesions (cervical, vulvar, vaginal and anal) and cervical and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types.
Croatian: Cervarix je cjepivo za primjenu u dobi od 9 godina za prevenciju premalignih anogenitalnih lezija (cervikalnih, vulvarnih, vaginalnih i analnih) te karcinoma cerviksa i anusa uzročno povezanih s određenim onkogenim tipovima humanog papilomavirusa (HPV).
English: 12-month persistent infection
Croatian: 12-mjesečna perzistentna infekcija
English: 6M PI and/or CIN1+ 6M PI
Croatian: CIN1+ 6M PI
English: In study HPV-008, the incidence of high grade cervical lesions was compared between the placebo and vaccine group irrespective of the HPV DNA type in the lesion.
Croatian: U ispitivanju HPV-008, incidencija cervikalnih lezija visokog stupnja je uspoređena između placeba i cijepljene grupe neovisno o tipu HPV DNA u leziji.
English: Immune response to Cervarix after the primary vaccination course
Croatian: Imunogenost Imunološki odgovor na Cervarix nakon primarnog cijepljenja
English: Sodium dihydrogen phosphate dihydrate Water for injections
Croatian: natrijev klorid natrijev dihidrogenfosfat dihidrat voda za injekcije
English: From 15 years and above Three doses each of 0.5 ml at 0, 1, 6 months** *If the second vaccine dose is administered before the 5th month after the first dose, a third dose should always be administered.
Croatian: Tri doze od 0,5 ml po rasporedu: 0, 1, 6 mjeseci** *Ako se druga doza cjepiva primijeni prije 5. mjeseca nakon prve doze, uvijek se mora primijeniti i treća doza.
English: However, it is unknown whether vaccine-induced antibodies are excreted in human breast milk.
Croatian: Međutim, nije poznato izlučuju li se cjepivom inducirana protutijela i u majčino mlijeko u ljudi.
English: If you are pregnant, if pregnancy occurs during the course of vaccination or if you are trying to become pregnant it is recommended to postpone or interrupt vaccination until after completion of the pregnancy.
Croatian: Ako ste trudni, ako tijekom ciklusa cijepljenja nastupi trudnoća ili ako pokušavate zatrudnjeti, preporučuje se odgoditi ili prekinuti cijepljenje do završetka trudnoće.
English: This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially “sodiumfree”.
Croatian: Ovo cjepivo sadrži manje od 1 mmol (23 mg) natrija po dozi, tj. zanemarive količine natrija.
English: If Cervarix is to be given at the same time as another injectable vaccine, the vaccines should always be administered at different injection sites (see section 4.5).
Croatian: Ako Cervarix treba primijeniti istodobno s nekim drugim injekcijskim cjepivom, ta cjepiva uvijek treba injicirati na različitim mjestima (vidjeti dio 4.5).